Last checked at 12 Apr 2019 07:00
12 April 2019
Ixico plc
("Ixico" or "the Company")
Change of Nominated Adviser & Sole Broker
Change of adviser
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, is pleased to announce the appointment, with immediate effect, of Cenkos Securities plc as its Nominated Adviser and sole broker.
Contacts
IXICO plc | +44 (0) 20 3763 7498 |
Giulio Cerroni, Chief Executive Officer |
|
|
|
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0) 20 7397 8900 |
Giles Balleny / Max Gould (Corporate Finance) |
|
Michael F Johnson / Russell Kerr (Sales) |
|
|
|
Optimum Strategic Communications | +44 (0) 203 950 9144 |
Mary Clark / Anne Marieke Ezendam / Supriya Mathur |
|
ixico@optimumcomms.com |
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes. www.ixico.com